NIPH Clinical Trials Search

PD&ARNI

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Chronic kidney disease G5D Peritoneal dialysis patient with hypertension
Date of first enrollment	19/05/2025
Target sample size	20
Countries of recruitment
Study type	Interventional
Intervention(s)	Oral administration of sacubitril valsartan

Outcome(s)

Primary Outcome	Changes in LVEF 3 and 6 months after taking Sacubitril Valsartan compared to before administration
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Both
Include criteria	Patients who meet all of the following criteria will be included. 1. Adult patients, regardless of gender, who visit the Department of Nephrology at Yamanashi University Hospital and have been undergoing peritoneal dialysis for at least six months. 2. Peritoneal dialysis patients with hypertension. 3. Patients who can provide written informed consent to participate in this study. Consent must be given by the individual.
Exclude criteria	1.Patients who meet the contraindications for sacubitril valsartan 2.Patients who were taking sacubitril valsartan before enrollment in the study 3.If a doctor determines that the person is unsuitable for the program